MetaCap

Alto Neuroscience Inc. (ANRO)

NYSE: ANROHealth CareBiotechnology: Pharmaceutical PreparationsUSD

25.37-1.14 (-4.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ANRO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.32
52-week range
12.51 – 37.48
Day range
24.40 – 26.48
Volume / Avg
522.53K / 614.92K
Beta
—

52-week range

$12.51$37.48

ANRO stock today

Shares of Alto Neuroscience (ANRO) finished lower on Nov 20 at $25.37, a drop of 4.30% or $1.14 per share, versus the S&P 500's 3.70% decline. At this level, ANRO sits in the middle of its 52-week range of $12.51 to $37.48: 32.3% below the high, set on Aug 25, 2026 and 102.8% above the low. ANRO is up 42.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 91.5%.

Alto Neuroscience has posted a net loss over the last twelve months (EPS of -$2.32), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alto Neuroscience

Company profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Amit Etkin M.D., Ph.D.
Headquarters
Mountain View, CA
Employees
68
IPO year
2024

Financial highlights

Full financials

Alto Neuroscience reported a net loss of $63.2 million, compared with a loss of $61.4 million a year earlier. Diluted earnings per share came in at -$2.19.

Alto Neuroscience annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-63.24M$-61.43M$-36.30M
EPS (diluted)$-2.19$-2.50$-9.73

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$38.67+52.42%

  • Strong buy 0
  • Buy 10
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $26.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.54 vs $-0.60
Surprise
+10.00%

ANRO news

All ANRO news

Alto Neuroscience peers

Health Care sector
ANRO peer companies
CompanyPrice% ChgMarket capCompare
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs ANRO
NKTRNektar Therapeutics30.20-7.19%$1.03Bvs ANRO
OMEROmeros Corporation13.21-5.71%$983.66Mvs ANRO
JBIOJade Biosciences Inc.15.31+1.66%$1.06Bvs ANRO
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs ANRO
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs ANRO
KARDKardigan Inc.11.54-7.83%$1.08Bvs ANRO
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs ANRO

Indexes, lists and sector

Alto Neuroscience stock FAQ

What is Alto Neuroscience's stock price today?

ANRO last traded at $25.37 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.

Who is Alto Neuroscience's CEO?

Dr. Amit Etkin M.D., Ph.D. is the chief executive officer of Alto Neuroscience Inc., which has about 68 employees.

What is the ANRO 52-week high?

The 52-week high for ANRO is $37.48 and the 52-week low is $12.51. The stock is currently 32.3% below its high.

Compare ANRO